AR and breast cancer: Applying bicalutamide in AR+ but HR-negative advanced BC patients resulted in a clinical benefit rate of 19% (14) and in a multicenter single-arm trial in women with AR+, metastatic or inoperable locally advanced TNBC, the combination of abiraterone acetate plus prednisone was only beneficial for some patients with molecular apocrine tumors (16).